Novavax
Novavax is a biotechnology company specializing in the development of vaccines for infectious diseases using innovative recombinant protein-based technology and adjuvant systems.
Company Overview
Novavax is dedicated to developing innovative vaccines aimed at combating infectious diseases such as COVID-19, seasonal influenza, RSV, Ebola, MERS, and SARS. Employing its proprietary recombinant protein-based nanoparticle vaccine technology alongside Matrix-M adjuvant technology, Novavax delivers advanced immunization solutions to tackle global health threats.
Vaccine Technology
Novavax utilizes a proprietary recombinant protein-based nanoparticle vaccine technology and Matrix-M adjuvant technology in its vaccine development. This approach enhances the immune response and improves the efficacy of vaccines. The company's flagship product, the Novavax COVID-19 Vaccine, is available under various trade names globally, including Covovax™ and Nuvaxovid™.
Global Collaborations
Novavax engages in extensive global collaborations with a range of partners, including biopharma organizations, research institutions, government agencies, and foundations. These partnerships are crucial in advancing vaccine development and ensuring the broad distribution and accessibility of vaccines globally.
Commitment to Equity and Transparency
Novavax is committed to equitable access and transparency in vaccine distribution and information dissemination. The company actively participates in clinical trials and investigations to improve vaccine efficacy and address public health threats. Novavax provides extensive resources through its Insights articles, promoting public awareness and education on vaccine technology and public health.
Compliance and Ethical Standards
Novavax operates a comprehensive compliance program designed to adhere to legal and ethical standards in vaccine development and distribution. This ensures that all operations and processes align with global health regulations and ethical practices, fostering trust and integrity in the company's mission to improve global health through innovative vaccines.